InVivo gets FDA OK to test bioscaffold in acute SCI patients

04/8/2013 | RTT News

InVivo Therapeutics has received investigational device exemption approval from the FDA to evaluate the use of its biopolymer scaffold in treating patients with acute spinal cord injuries. The study will take place over 15 months, and the company hopes to submit to the FDA the details of the trial by the end of next year.

View Full Article in:

RTT News

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr. Regulatory Specialist, Biotech Center of Expertise
BASF, The Chemical Co.
San Diego, CA
Food Lawyer
Cargill
Wayzata, MN
Actuary
Meridian Health Plan
Detroit, MI
Vice President of Finance
Urban Health Plan, Inc.
Bronx, NY
Director of Payor/Provider Contracting
U.S. Medical Management
Tryo, MI